Literature DB >> 24494707

Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.

May Hagiwara1, Thomas E Delea, Karen Chung.   

Abstract

BACKGROUND: Patients with bone metastases secondary to breast cancer are pre-disposed to skeletal-related events (SREs), including spinal cord compression (SCC), pathologic fracture (PF), surgery to bone (SB), and radiotherapy to bone (RT).
OBJECTIVE: To document current patterns of healthcare utilization and costs of SREs in patients with breast cancer and bone metastases.
METHODS: This was a retrospective, observational study using the Thomson MedStat MarketScan Commercial Claims and Encounters database from 9/2002 to 6/2011. Study subjects included all persons with claims for breast cancer and for bone metastases, and ≥1 claims for an SRE. Unique SRE episodes were identified based on a gap of at least 90 days without an SRE claim, and classified by treatment setting (inpatient or outpatient) and SRE type (SCC, PF, SB, or RT).
RESULTS: Of 17,266 patients with breast cancer and bone metastases, 9142 (53%) had one or more SRE episodes. Among 5809 patients who met all other criteria, there were 7617 SRE episodes over mean (SD) follow-up of 17.2 (15.2) months. The percentage of episodes that required inpatient treatment ranged from 11% (RT) to 76% (SB). On average, inpatient SCC episodes (n=83 episodes) were most costly; while outpatient PF episodes (n=552 episodes) were least costly. Of the total SRE costs (mean [SE] $21,072 [$36,462]/episode), 36% were attributable to outpatient RT (n=5265 episodes) and 31% to inpatient PF (n=838 episodes). LIMITATIONS: The administrative claims data used in this study may lack sensitivity and specificity for identification of clinical events and may not be generalizable to other populations. Also, for some SRE episode categories, the number of events was small and cost estimates may lack precision.
CONCLUSION: In patients with breast cancer and bone metastases, SREs are associated with high costs and hospitalizations.

Entities:  

Mesh:

Year:  2014        PMID: 24494707     DOI: 10.3111/13696998.2014.890937

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  10 in total

1.  Management of Potential Long-Term Toxicities in Breast Cancer Patients.

Authors:  C C O'Sullivan; K J Ruddy
Journal:  Curr Breast Cancer Rep       Date:  2016-10-13

2.  [Kyphoplasty combined with intraoperative radiotherapy (Kypho-IORT). Alternative therapy for patients with oligometastatic spinal metastases].

Authors:  F Bludau; T Reis; F Schneider; S Clausen; F Wenz; U Obertacke
Journal:  Radiologe       Date:  2015-10       Impact factor: 0.635

3.  Discharge status and post-discharge healthcare costs after skeletal-related event hospitalizations among medicare patients with bone metastatic solid tumors or multiple myeloma.

Authors:  Suying Li; Haifeng Guo; Yi Peng; Tingting Gong; Alan Fu; Debajyoti Bhowmik; Rohini K Hernandez; Katherine B Carlson; Kimberly A Lowe; Jitesh Rana; Shuling Li
Journal:  J Bone Oncol       Date:  2020-10-21       Impact factor: 4.072

Review 4.  Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities.

Authors:  Jaime M Preussler; Lih-Wen Mau; Navneet S Majhail; Christa L Meyer; Ellen M Denzen; Kristen C Edsall; Stephanie H Farnia; Alicia Silver; Wael Saber; Linda J Burns; David J Vanness
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-14       Impact factor: 5.742

5.  Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer.

Authors:  Arif Hussain; Candice Yong; Katherine H R Tkaczuk; Yi Qian; Jorge Arellano; C Daniel Mullins; Eberechukwu Onukwugha
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.752

6.  Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events.

Authors:  Fränce Hardtstock; Zeki Kocaata; Thomas Wilke; Axel Dittmar; Marco Ghiani; Vasily Belozeroff; David J Harrison; Ulf Maywald; Hans Tesch
Journal:  Eur J Health Econ       Date:  2021-01-18

Review 7.  Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.

Authors:  Chirayu M Patel; Thaddeus J Wadas; Yusuke Shiozawa
Journal:  Molecules       Date:  2021-04-09       Impact factor: 4.411

8.  Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction.

Authors:  Jungho Back; Minh Nam Nguyen; Lu Li; Saelim Lee; Inkyu Lee; Fancheng Chen; Lauren Gillinov; Yeon-Ho Chung; Kareme D Alder; Hyuk-Kwon Kwon; Kristin E Yu; Christopher M Dussik; Zichen Hao; Michael J Flores; Yoseph Kim; Izuchukwu K Ibe; Alana M Munger; Sung Wook Seo; Francis Y Lee
Journal:  Bone Res       Date:  2021-09-29       Impact factor: 13.362

9.  Cost Analysis With Use of Expandable Cage or Cement in Single level Thoracic Vertebrectomy in Metastasis.

Authors:  Miki Katzir; Tarush Rustagi; Jeffrey Hatef; Ehud Mendel
Journal:  Global Spine J       Date:  2020-12-14

10.  Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US.

Authors:  Leah J McGrath; Robert A Overman; Diane Reams; Karynsa Cetin; Alexander Liede; Steven A Narod; M Alan Brookhart; Rohini K Hernandez
Journal:  Clin Epidemiol       Date:  2018-09-26       Impact factor: 4.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.